Sulindac Sulfide-induced Apoptosis Involves Death Receptor 5 and the Caspase 8-dependent Pathway in Human Colon and Prostate Cancer Cells

Ying Huang, Qin He, Michael J. Hillman, Rong Rong, and M. Saeed Sheikh

Department of Pharmacology, State University of New York Upstate Medical University, Syracuse, New York 13210

ABSTRACT

Sulindac is the most extensively investigated clinically relevant chemopreventive nonsteroidal anti-inflammatory drug. Sulindac sulfide is one of the major metabolites of sulindac that is believed to mediate its antimutagenic effects by inducing apoptosis. Recent evidence suggests that sulindac sulfide engages the mitochondrial pathway involving caspase 9 and Bax to mediate its apoptotic effects [Zhang et al., Science (Wash. DC), 290: 989–992, 2000]. In this report, we demonstrate that sulindac sulfide also engaged the membrane death receptor (DR) pathway to mediate apoptosis. Sulindac sulfide up-regulated DR5 and activated the proximal caspase 8 in various different colon and prostate cancer cell lines. Sulindac sulfide specifically up-regulated the DR5 levels but had no effect on the levels of other DRs including DR4, Fas, and tumor necrosis factor receptor 1. To further delineate the role of DR5 in sulindac sulfide-induced apoptosis, we used JCA-1 prostate cancer cells that are deficient in mounting a Fas and tumor necrosis factor receptor 1-dependent apoptotic response but are proficient in mediating DR5-dependent apoptosis. JCA-1 cells were stably transfected with dominant-negative Fas-associated death domain to block the flow of apoptotic signals originating from the endogenous DR5, and sulindac sulfide-induced apoptosis was investigated. Our results indicated that by blocking the DR5-dependent apoptotic pathway, dominant-negative Fas-associated death domain did indeed inhibit sulindac sulfide-induced apoptosis. Furthermore, exogenous tumor necrosis factor-related apoptosis-inducing ligand, the ligand for DR5, also potentiated sulindac sulfide-induced apoptosis in all of the cell lines tested, thereby further supporting the involvement of DR5 in sulindac sulfide-induced apoptosis. Thus, our results demonstrate that sulindac sulfide also engages the membrane DR pathway involving DR5 and proximal caspase 8 to induce apoptosis.

INTRODUCTION

NSAIDs are well known for their analgesic, antipyretic, and anti-inflammatory effects. NSAIDs are believed to mediate their effects by inhibiting two COX isoenzymes, COX-1 and COX-2 (reviewed in Ref. 1). Both COX-1 and COX-2 catalyze the formation of prostaglandins from arachidonic acid, and whereas COX-1 is constitutively expressed, COX-2 is an inducible enzyme (reviewed in Ref. 1). A number of studies have demonstrated that the regular use of NSAIDs can reduce the risk of colon cancer (reviewed in Refs. 1–3). There are a number of studies have demonstrated that the regular use of NSAIDs can reduce the risk of colon cancer (reviewed in Refs. 1–3). There are also reports suggesting beneficial effects of NSAIDs in the prevention of lung, esophageal, and stomach cancers (reviewed in Ref. 4). In fact, the National Cancer Institute is currently sponsoring clinical trials to investigate the efficacy of COX-2-selective NSAIDs in the prevention and treatment of colon, skin, and bladder cancer. The mechanisms by which the NSAIDs mediate their chemopreventive and antimutagenic effects remain less well understood but may be multifaceted in nature. Evidence suggests that the chemopreventive effects of NSAIDs could be attributed to their apoptosis-inducing potential. For example, sulindac is the most extensively investigated clinically relevant chemopreventive NSAID that reduces the number and size of the colorectal tumors in genetically susceptible humans and animals (5–7). Sulindac sulfide and sulindac sulfone are the two major metabolites of sulindac; sulindac sulfide is COX selective, whereas sulindac sulfone is believed to lack COX-inhibitory activity (8). Both sulindac metabolites have been reported to induce apoptosis in various different cell types (8–11). Despite the fact that NSAIDs are important cancer chemopreventive agents that induce apoptosis, relatively little is known about the molecular and biochemical mechanisms of NSAID-induced apoptosis. Clearly, more studies are needed to fully elucidate the molecular and biochemical pathways of NSAID-induced apoptosis.

A wealth of information supports the notion that apoptosis is controlled via two major apoptotic pathways, one that originates at the membrane and another that involves the mitochondria (reviewed in Refs. 12–14). The apoptotic pathways originating at the membrane involve membrane DRs such as Fas, TNF-R1, DR3, DR4, and DR5 (reviewed in Refs. 12–14). These DRs are activated by their respective ligands and engage the intracellular apoptotic machinery involving adaptor molecules and proximal as well as distal (executioner) caspases. TNF-α, Fas ligand, and Apo3L are ligands for TNF-R1, Fas, and DR3, respectively, whereas TRAIL (also known as Apo2L) activates DR4 and DR5 (reviewed in Refs. 12–14). Agonist antibodies or overexpression also activates these DRs, albeit in a ligand-independent manner. Ligand-dependent or -independent activation of DRs results in the recruitment of the intracellular adaptor molecules that further engage the intracellular proximal caspase 8 at the receptor site (reviewed in Refs. 12–14). For example, activated TNF-R1 and DR3 sequentially recruit the intracellular adaptor molecules TRADD, FADD, and proximal caspase 8, which results in the flow of apoptotic signals further downstream. The DR Fas does not interact with TRADD but directly recruits FADD to activate the proximal caspase 8 (reviewed in Refs. 12–14). Although evidence from FADD knockout cells suggests that FADD may not be absolutely required for DR4-mediated apoptosis (15), a number of recent studies demonstrate that both DR4 and DR5 independently interact with FADD to engage and activate proximal caspase 8 (16–20).

The apoptotic events engaging the mitochondrial pathway affect mitochondrial permeability and the release of cytochrome c from the mitochondria into the cytosol (reviewed in Ref. 21). In the presence of ATP/dATP, cytosolic cytochrome c interacts with apaf1 and procaspase 9, which results in the activation of caspase 9 and the downstream caspases (reviewed in Ref. 21). A large body of evidence suggests that Bcl-2 or Bcl-xL inhibits the release of cytochrome c from the mitochondria and consequently blocks apoptosis induced by a variety of agents. By contrast, Bax and Bid, the proapoptotic members of the Bcl-2 family, are believed to mediate their apoptotic effects by increasing the release of cytochrome c from the mitochondria (reviewed in Ref. 21).

In a recent study, Zhang et al. (11) have reported that the NSAIDs...
sulindac sulfide and indomethacin mediate apoptosis by engaging the mitochondrial pathway involving caspase 9 and Bax in human colon cancer cells. They further demonstrated that the disruption of the BAX gene in human colon cancer cells abrogated the apoptosis mediated by these NSAIDs (11). We undertook this study to investigate whether NSAID-mediated apoptosis also involves membrane DRs and proximal caspase 8. Here we report, for the first time, that the NSAID sulindac sulfide also engages DR5 and proximal caspase 8 to mediate apoptosis in human colon and prostate cancer cells.

MATERIALS AND METHODS

Materials. Sulindac sulfide and sulindac sulfone were provided by Merck (Rahway, NJ). Recombinant TNF-α was purchased from Sigma Chemical Co. (St. Louis, MO). Anti-human DR5 antibody was purchased from Alexius Biochemicals (San Diego, CA), anti-human pro-caspase 8 antibody was purchased from PharMingen (San Diego, CA), anti-human FADD and anti-human Fas antibodies were purchased from Transduction Laboratories (Lexington, KY), and anti-human β-actin antibody was purchased from Sigma Chemical Co. Anti-TNF-R1 antibody and recombinant DR5-Fc were obtained from R&D Systems (Minneapolis, MN). Dr. Avi Ashkenazi (Genentech, San Francisco, CA) kindly provided TRAIL.

Cell Lines and Cell Culture. HT29 and HCT116 human colon cancer cells and DU145, JCA-1, and TSU-Pr1 human prostate cancer cells were regularly maintained in DMEM (Life Technologies, Inc., Gaithersburg, MD) supplemented with 10% fetal bovine serum (Gemini Bioproducts, Calabasas, CA).

Analysis for Apoptosis. Cells exhibiting morphological features of apoptosis were detected as described previously (22, 23). Briefly, floating and adherent cells were fixed with methanol, stained with 4’,6-diamidino-2-phenylindole solution, and examined under a fluorescent microscope using a 20 nm filter. The apoptotic cells exhibiting morphological features of apoptosis including chromatin condensation and nuclear fragmentation were counted in 5–10 randomly selected fields. Approximately 300–1000 nuclei were examined for each sample, and the results were expressed as the number of apoptotic nuclei divided by the total number of nuclei counted.

Northern Blotting. RNA extraction and Northern blot analyses were performed as described previously (22). A human DR5 cDNA probe was used as reported previously (22). A RT-PCR-amplified human DR4 cDNA corresponding to the 3′ region was used to analyze DR4 expression.

Western Blotting. Western blot analyses were performed as described previously (23). To detect DR5, an anti-human DR5 antibody (Alexis Biochemicals) was used. The specificity of the antibody was confirmed by using recombinant DR5 protein as a positive control (R&D Systems).

Caspase 8 Activity Assay. Cells were either untreated or treated with sulindac sulfide for various lengths of time and harvested to measure caspase 8 activity by using Ac-IETD-AFC caspase 8 fluorogenic substrate (PharMingen). In brief, floating and adherent cells were pooled, centrifuged, and washed with PBS, and cell pellets were dissolved in lysis buffer [10 mM Tris-HCl (pH 7.5), 10 mM NaPPi, 1% Triton X-100, and 10 mM NaH2PO4/Na2HPO4] (5). Liberation of AFC from Ac-IETD-AFC (designated as caspase 8 activity) was detected by using a spectrofluorometer (FL3–7.5), 10 mM NaPPi, 1% Triton X-100, and 10 mM NaH2PO4/Na2HPO4. Protein added to a microcentrifuge tube containing 500 μl of assay buffer [20 mM HEPES (pH 7.2), 100 mM NaCl, 10 mM DTT, 1 mM EDTA, 0.1% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid, and 10% sucrose]. Equal amounts of protein representing untreated or sulindac sulfide-treated cells were then added to corresponding tubes and incubated for approximately 1 h at 37°C. Liberation of AFC from Ac-IETD-AFC (representing caspase 8 activity) was detected by using a spectrofluorometer (FL3–21) with an excitation wavelength of 400 nm and an emission wavelength of 480–520 nm.

Stable Transfection. The expression vector pcDNA3-FADD-DN [kindly provided by Dr. Vishva Dixit (Genentech)] was used to generate the stable transfectants. This expression vector carries the cDNA insert of human FADD-DN under the control of the cytomegalovirus promoter. The same expression vector without the insert was used for control transfection. JCA-1 cells plated at a density of 1 × 105 cells/100-mm plate were transfected with SuperFect reagent (Qiagen, Valencia, CA) per the manufacturer’s instructions. Selection was carried out in G418 (600 μg/ml), and the resistant colonies were selected after approximately 4 weeks. Several isolated clones were selected, and the positive clones were identified by Western blotting using an anti-FADD antibody (Transduction Laboratories).

Quantitative RT-PCR. RT-PCR was performed using the SuperScript First Strand Synthesis System (Life Technologies, Inc.) per the manufacturer’s protocols. Two μg of total RNA were used in each reaction. cDNA was diluted in series of 1:10, 1:200, and 1:4000. For PCR amplification, 5.25 μl of each diluted cDNA were mixed with 1 unit of Taq DNA polymerase (Promega), 10 mM deoxynucleotide triphosphate, 2.5 mM MgCl2, and 2.5 pmol of the following primers in a 25-μl total volume: TRAIL-S (5′-CTCAAGTGTGTAT-CACAGTAGT-3′); TRAIL-AS (5′-CGATTCTTCTGCTACGCCCTCTCA-3′); β-Actin-S (5′-TGTITGGAGACCCCTAACCC-3′); and β-Actin-AS (5′-AAGCTGTGTTGGCGTACAG-3′).

Samples were subjected to amplification cycles consisting of 95°C for 45 s, 61°C for 45 s, and 72°C for 45 s. Aliquots of 10 μl of each PCR product were analyzed by 2% agarose gel electrophoresis and ethidium bromide staining.

RESULTS AND DISCUSSION

Fig. 1A illustrates the morphological features of sulindac sulfide-induced apoptosis in one representative JCA-1 human prostate cancer cell line. Sulindac sulfide-treated prostate cancer cells exhibit char-
characteristic features of apoptosis including chromatin condensation and nuclear fragmentation (Fig. 1A). Fig. 1B shows quantitative data on sulindac sulfide-induced apoptosis in various human prostate and colon cancer cells. Although sulindac sulfone at equimolar concentrations did not induce cell death in the same panel of cell lines, it did induce varying degrees of apoptosis when used at higher concentrations (data not shown). DR4 and DR5 are the newly discovered membrane DRs that are activated by their ligand, TRAIL (reviewed in Refs. 12–14). DR5, but not DR4, has recently been identified as a downstream effector of p53 (24). In our recent studies, we have demonstrated that DR5 is regulated in a p53-dependent and -independent manner during genotoxic and nongenotoxic stress-induced apoptosis (22). DR5 regulation occurs in a stimulus-specific manner because several potent apoptosis-inducing agents (genotoxic and nongenotoxic) do not regulate DR5 (22). To further investigate whether sulindac sulfide-induced apoptosis involves DR4 and DR5 and their ligand, TRAIL, we examined the effects of sulindac sulfide on the expression of these molecules in a panel of colon and prostate cancer cell lines, including HCT116, HT29, DU145, JCA-1, and TSU-Pr1. Our results, which are presented in Fig. 2A, indicate that sulindac sulfide up-regulates DR5 mRNA levels in all of the cell lines examined. The induction of DR5 expression by sulindac sulfide appears to be p53 independent because it is regulated in p53-positive (HCT116) and p53-negative (HT29, DU145, JCA-1, and TSU-Pr1) cells. Fig. 2A also shows the kinetics of DR5 mRNA induction by sulindac sulfide. A modest increase in the DR5 mRNA levels was seen as early as after 2 h of sulindac sulfide treatment and became more remarkable by 4–6 h of sulindac sulfide treatment. Because sulindac sulfide-induced morphological features of apoptosis were not detected by 4–6 h, these results suggest that DR5 mRNA induction occurs before sulindac sulfide-induced apoptosis.

The sulfone metabolite had no effect on DR5 expression when used at an equimolar concentration (data not shown). At higher concentrations, however, sulindac sulfone did regulate DR5 expression, but the effect was less pronounced than that noted with lower concentrations of sulindac sulfide. A representative Northern blot in Fig. 2B illustrates the effects of 400 and 500 μM sulindac sulfone on DR5 regulation in HCT116 and JCA-1 cells, respectively. Weak induction of DR5 by 600 μM sulindac sulfone was also noted in DU145 cells (data not shown). DR4 is the second DR that is activated by TRAIL. Consistent with previous reports (22, 25), we also detected multiple transcripts of the DR4 gene in these cell lines (Fig. 2C). However, unlike DR5, DR4 expression was not regulated by sulindac sulfide (Fig. 2C), although the DU145 prostate cancer cell line exhibited a modest increase in DR4 mRNA expression (Fig. 2C); the significance of this change on the overall DR4 levels remains to be investigated. Next, we investigated the effects of sulindac sulfide on TRAIL (the DR5 ligand) gene expression. Because the TRAIL cDNA probe cross-hybridized with several nonspecific transcripts, Northern blotting was not informative. RT-PCR was therefore used to investigate the expression of TRAIL and its regulation by sulindac sulfide in these cells. All cell lines were found to express TRAIL mRNA, albeit differentially, but sulindac sulfide did not regulate its expression. Fig. 2D shows representative results indicating the lack of effect of sulindac sulfide on TRAIL mRNA regulation in HT29 human colon cancer cells. To ensure that these results were not due to a PCR artifact, we confirmed the DR5 mRNA induction using similar RT-PCR conditions (data not shown).

To determine whether sulindac sulfide-induced DR5 mRNA up-regulation was coupled with similar changes at the protein levels, Western blot analyses were performed using commercially available antihuman DR5 antibodies. Our results indicated that sulindac sulfide also enhanced DR5 protein levels (Fig. 2E). It is noteworthy that the two-band pattern of the endogenous DR5 protein is consistent with previous published results (26).

\[ \text{Unpublished results.} \]
Sulfide-treated DU145 cells. Cells were either untreated or treated with 200 μM sulindac sulfide for the indicated time periods (in h). Floating and adherent cells were pooled and subjected to a caspase 8 activity assay as described in Materials and Methods. A, decrease in the levels of pro-caspase 8 (indicating its activation) was seen in sulindac sulfide-treated cells (DU145 and JCA-1) when the levels of DRs are increased through endogenous induction or exogenous overexpression. Exogenously overexpressed DR5, without concomitant increases in the levels of its ligand, has been shown to induce apoptosis (24, 27–29). Up-regulation of endogenous DR5 by several genotoxic and nongenotoxic agents is also associated with induction of apoptosis (22). Our results indicate that sulindac sulfide-induced apoptosis is coupled with DR5 induction without changes in the expression of its ligand, TRAIL (Fig. 2D). It is therefore possible that sulindac sulfide may activate DR5 to induce cell death in a ligand-independent manner. Alternatively, or coupled with this possibility, sulindac sulfide, by increasing the levels of endogenous DR5, may sensitize these cells to pre-existing TRAIL that is known to exist as a soluble as well as a type II cell surface protein. Our results suggest that this could be a possibility because these cells do express TRAIL mRNA (Fig. 2D; data not shown).

Caspase 8 is one of the most proximal caspases activated by signals originating at the membrane DRs including DR5. We reasoned that if sulindac sulfide up-regulation of DR5 results in activation of this membrane DR (regardless of whether it is ligand dependent or independent), then caspase 8 should also be activated in these cells. We therefore investigated the effects of sulindac sulfide on caspase 8 activation, and the results presented in Fig. 3A indicate that sulindac sulfide did indeed activate caspase 8 in all of the cell lines in which it also induced DR5 expression. Sulindac sulfone did not induce caspase 8 activation at an equimolar concentration (Fig. 3A); however, at a higher concentration (400–600 μM), some activation of caspase 8 was observed, but the effect was less pronounced than that noted with sulindac sulfide (data not shown). Caspase 8 (like other caspases) exists in an inactive form as a pro-caspase, and its activation involves cleavage of the pro-form into smaller active subunits. Thus, the decrease in the level of pro-caspase 8 as shown in Fig. 3A reflects its activation (30–33). The same blots were probed with anti-actin antibody to demonstrate comparable loading of the samples in each lane (Fig. 3A).

To further confirm caspase 8 activation, we performed a caspase 8 activity assay. Ac-IETD-AFC caspase 8 fluorogenic substrate (PharMingen) was used to measure caspase 8 activity in the lysates of untreated and sulindac sulfide-treated DU145 cells. The representative results shown in Fig. 3B indicate that the cleavage of Ac-IETD-AFC, representing caspase 8 activity, increased in sulindac sulfide-treated cells within approximately 15 h. Together, these results demonstrate that caspase 8 is activated during apoptosis induced by sulindac sulfide. We further reasoned that if caspase 8 activation was critical for sulindac sulfide-induced apoptosis, then caspase 8 inhibitor should block/inhibit sulindac sulfide-mediated apoptosis. Therefore, we used a cell-permeable caspase 8 inhibitor, z-IETD-FMK (R&D Systems), to test its effect on sulindac sulfide-induced apoptosis. As shown in Fig. 3C, caspase 8 inhibitor clearly inhibits sulindac sulfide-induced apoptosis.

Caspase 8 inhibitor z-IETD-FMK (20 μM). The inhibitor was added 30 min before the addition of sulindac sulfide, and apoptotic cells were analyzed after approximately 24 h of sulindac sulfide treatment. The values represent the means of two independent experiments for DU145 and one experiment for JCA-1 cells. Bars, SE. D, effect of sulindac sulfide on the expression of DRs Fas and TNF-R1 in DU145 and HCT116 cells. Cells were treated with vehicle (C) or sulindac sulfide for the indicated periods of time (in h); Western blot analyses were performed using anti-Fas and anti-TNF-R1 antibodies. Jurkat and human endothelial cell lysates serving as positive controls for Fas and TNF-R1, respectively, were analyzed simultaneously on the same membranes. The same blots were also probed with anti-β-actin antibody to demonstrate comparable loading.
Caspase 8 is predominantly activated by signals originating at the membrane DRs. It was possible that sulindac sulfide, in addition to activating DR5, might also activate other DRs. We therefore investigated whether sulindac sulfide also regulates other DRs. Representative results in Fig. 3D indicate that both cell lines did not exhibit detectable Fas and TNF-R1, and sulindac sulfide did not enhance their levels. The lysates of Jurkat and human endothelial cells serving as positive controls for Fas and TNF-R1, respectively, were used on the same membranes to confirm that the antibodies were working (Fig. 3D). It is possible that DU145 and HCT116 cells may exhibit very low levels of Fas and TNF-R1 that cannot be detected by Western blotting.

DR3 is expressed primarily by cells and tissues of lymphoid origin (reviewed in Refs. 12 and 13). Northern blot analyses revealed that untreated or sulindac sulfide-treated cells also did not exhibit detectable DR3 mRNA (data not shown). Therefore, these results suggest that sulindac sulfide may predominantly engage DR5, but not Fas, TNF-R1, and DR3, to mediate its apoptotic effects.

Recent studies demonstrate that DU145 and JCA-1 human prostate cancer cells are resistant to Fas ligand-induced apoptosis and thus have a defective Fas-mediated apoptotic signaling pathway (Ref. 34 and the references therein). To further investigate whether these two cell lines harbor intact TNFR-1 and/or DR5-dependent apoptotic pathways, we treated these cells with TNF-α, the TNF-R1 ligand, and with TRAIL, the DR5 ligand. Our results indicated that both the DU145 and JCA-1 cell lines are resistant to TNF-α (data not shown) but sensitive to TRAIL-induced apoptosis (see below). These results suggest that, in addition to a defective Fas pathway, both of these cell lines also harbor a defective TNF-R1-dependent apoptotic pathway. However, both of these cell lines are proficient in mounting a TRAIL-mediated DR5-dependent apoptotic response. These results, coupled with our other findings that these cells also do not express DR3 and that sulindac sulfide does not regulate DR4 (Fig. 2C), strongly implicate DR5 as the predominant DR that is regulated and activated during sulindac sulfide-mediated apoptosis.

To further investigate the contribution of DR5 in sulindac sulfide-induced apoptosis, we established stable transfectants expressing FADD-DN in JCA-1 cells. We chose JCA-1 cells and FADD-DN for the following reasons: (a) JCA-1 cells do not express DR3, and they harbor defective Fas and TNF-R1 pathways (Ref. 34 and this study); thus, sulindac sulfide may not engage these three DRs to mediate apoptosis in these cells; (b) JCA-1 cells do express DR4 and DR5 and are sensitive to TRAIL-mediated cell death; however, sulindac sulfide regulates DR5 but not DR4, and thus DR5 is likely to be the main DR mediating the apoptotic effects of this NSAID; and (c) FADD-DN has been shown to block/inhibit apoptosis induced by all of the known DRs including DR5 (15–19). Our results suggest that the other DRs including Fas, TNF-R1, DR3, and DR4 may not be involved in sulindac sulfide-mediated apoptosis. Thus, if DR5 plays an important role in sulindac sulfide-induced apoptosis, then the interruption of DR5-dependent apoptotic signal transduction by FADD-DN should inhibit/block cell death induced by this NSAID.

JCA-1 cells were transfected with expression vector carrying FADD-DN cDNA; control cells were transfected with the same vector without the FADD-DN cDNA insert. The exogenous FADD-DN lacks the death effector domain and thus migrates faster than the endogenous full-length FADD when analyzed on SDS-PAGE. As shown in Fig. 4A, several independently isolated clones express exogenous FADD-DN, whereas vector-only-transfected cells do not. We selected
three independent clones (clones 2, 4, and 8) to confirm the functionality of exogenous FADD-DN and found that all three clones displayed relative resistance to TRAIL-mediated apoptosis (data not shown). Therefore, we used clones 2, 4, and 8 in our subsequent experiments, and the results presented in Fig. 4B indicate that FADD-DN clearly inhibits sulindac sulfide-induced apoptosis. These results, coupled with our aforementioned findings, strongly implicate the DR5 pathway in sulindac sulfide-mediated apoptosis. To further explore the functional significance of sulindac sulfide up-regulation of endogenous DR5 levels, we investigated the effect of exogenous TRAIL on sulindac sulfide-mediated apoptosis. Results presented in Fig. 4C indicate that 50 ng/ml TRAIL (10 ng/ml for HCT116 cells) alone clearly induces apoptosis in these cells within 20 h of treatment. We therefore used lower doses of TRAIL (5 ng/ml) and sulindac sulfide (75 μM) to investigate their effects in combination. As shown in Fig. 4D, TRAIL clearly potentiates sulindac sulfide-mediated apoptosis in all of the cell lines in which sulindac sulfide also up-regulates the DR5 levels. These results further suggest that sulindac sulfide, by increasing the DR5 (but not DR4) levels, appears to sensitize these cells to killing by TRAIL.

In this study, we have presented evidence that sulindac sulfide mediates apoptosis by engaging the membrane DR DR5-dependent apoptotic pathway. A recent study (11) has demonstrated that sulindac sulfide engages the mitochondrial pathway involving caspase 9 and DR5 AND CASPASE 8 ACTIVATION BY SULINDAC SULFIDE. The mitochondrial apoptosis cascade is initiated by the release of cytochrome c from the mitochondria (35, 36). Whether Bid and/or other as yet unidentified molecules can also bridge such a cross-talk between the apoptotic signals originating at the membrane DRs and mitochondria (35, 36), Bid is an intracellular molecule that bridges the apoptotic interactions between the DRs Fas/TNF-R1 and the mitochondria (35, 36). Whether Bid and/or other as yet unidentified molecules can also bridge such a cross-talk between the apoptotic signals originating at DR4/DR5 and mitochondria is a possibility that remains to be investigated. Zhang et al. (11) have demonstrated that mitochondrial and postmitochondrial events appear to be important in sulindac sulfide-mediated apoptosis because deletion of Bax completely blocked sulindac sulfide-induced apoptosis in HCT116 human colon cancer cells. In our studies, we have demonstrated that sulindac sulfide appears to engage DR5 and proximal caspase 8. Although caspase 8 inhibitor and FADD-DN clearly inhibit sulindac sulfide-induced apoptosis, they did not completely block apoptosis induced by this NSAID in the human prostate cancer cells tested. Based on these findings, it is likely that sulindac sulfide would also engage other apoptotic pathways such as the mitochondrial pathway to fully execute apoptosis. Whether DR5 and caspase 8 activation resides upstream or downstream is an important question in mitochondrial events in sulindac sulfide-mediated apoptosis is an important issue that requires further investigation. Additional studies are also needed to explore the role of Bid in mediating interactions between DR5 and mitochondrial pathways during sulindac sulfide-mediated apoptosis.

Our results also indicate that the sulfone metabolite of sulindac did not regulate DR5, activate caspase 8, or induce apoptosis when tested at equimolar concentrations. However, at higher concentrations, sulindac sulfone did induce apoptosis and selectively up-regulate DR5 expression, but its effects were less pronounced than those noted with sulindac sulfide. Sulindac sulfide is known to inhibit COX activity, whereas sulindac sulfone does not (8). Therefore, it is possible that sulindac sulfide regulation of DR5 could occur independent of its effect on COX activity. Regardless of COX dependence or independence, the sulindac sulfide regulation of DR5 is a novel mechanism by which this NSAID may mediate its anticaner effects. In conclusion, we have demonstrated that sulindac sulfide, an important clinically relevant NSAID, mediates apoptosis by engaging DR5, and its effects can be potentiated with TRAIL. TRAIL has shown significant promise as a novel anticancer agent that selectively kills tumor cells and is well tolerated by animals (37). Recently, however, TRAIL has been shown to be more toxic to human hepatocytes than to animal hepatocytes (38). Thus, hepatic toxicity may limit the utility of TRAIL as a single anticancer agent. Based on our findings that TRAIL and sulindac sulfide exhibit synergy to mediate apoptosis, we propose that a combination of lower doses of TRAIL and sulindac sulfide (and perhaps other NSAIDs) could be a novel therapeutic strategy against prostate cancer, colon cancer, and other types of malignancies.

ACKNOWLEDGMENTS

We are thankful to Dr. Avi Ashkenazi (Genentech) for providing TRAIL and Vishva Dixit (Genentech) for the FADD-DN expression vector. We also thank Merck for providing sulindac sulfide and sulindac sulfone.

REFERENCES


Downloaded from cancerres.aacrjournals.org on July 19, 2017. © 2001 American Association for Cancer Research.
Sulindac Sulfide-induced Apoptosis Involves Death Receptor 5 and the Caspase 8-dependent Pathway in Human Colon and Prostate Cancer Cells

Ying Huang, Qin He, Michael J. Hillman, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/61/18/6918

Cited articles
This article cites 37 articles, 16 of which you can access for free at:
http://cancerres.aacrjournals.org/content/61/18/6918.full#ref-list-1

Citing articles
This article has been cited by 21 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/61/18/6918.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.